Historical vtrs News Stories
Viatris Moves: EpiPen Settlement & Strategy Shift.
Viatris (VTRS) closed a legacy EpiPen pricing case with a $60M settlement, announced a legal leadership departure, and outlined a strategy to pivot toward higher‑margin generics and specialty launches. Ongoing FDA scrutiny of its Indore facility remains a watch item but is currently described as low near‑term revenue risk.
Lilly, Novo Approvals Shift S&P 500 Winners Today!
This week’s concrete pharma developments — FDA approvals for Lilly’s oral GLP‑1 Foundayo and Novo Nordisk’s once‑weekly insulin Awiqli, plus deal activity from Lilly, Biogen and others — are creating identifiable upside for S&P 500 healthcare names and near‑term trading catalysts for investors.
Viatris 2030 Plan, Legal Shakeup, Wegovy Case Move
This week Viatris (VTRS) delivered a long-range 2030 financial roadmap at its March 19 investor event, announced a Chief Legal Officer transition effective April 1, and joined Novo Nordisk in filing a joint motion for final judgment in the Wegovy (semaglutide) patent dispute in Delaware—developments that reduce legal uncertainty and clarify strategic direction for shareholders.
Viatris Q4 Up, Nashik Fire, MR-141 PDUFA Oct172026
Viatris (VTRS) reported stronger Q4 and FY2025 results with improved adjusted EPS and robust free cash flow, while a Nashik plant fire temporarily halted production. The FDA accepted the MR-141 sNDA for presbyopia with a PDUFA date of October 17, 2026 — a material regulatory catalyst for the company’s evolving specialty strategy.
VTRS: Viatris Rally Ahead of Feb 26 Earnings
Viatris (VTRS) rallied in mid-February as investors positioned ahead of its Q4 and full‑year 2025 results on Feb 26 and a March 19 investor event. This article summarizes the concrete developments that directly affect VTRS, key data points, sector catalysts and clear implications for shareholders.
Viatris Hits 52-Week High After Strong Q3 Beat Now
Viatris (VTRS) surged to a 52-week high after a Q3 2025 earnings beat and raised guidance. Elevated trading volumes and renewed investor interest followed a string of gains in early February 2026.
Viatris Surges Ahead of Feb 26 Earnings Call Boost
Viatris (VTRS) climbed to new 52-week highs this week as investors position ahead of the company’s February 26 earnings release and a March 19 investor event. A senior legal leadership change also arrived, adding a governance angle to near-term catalysts.